Pharma

As resistance to traditional antibiotics reaches crisis levels, scientists are poised to forage in hard-to-reach sea trenches for new antimicrobials and novel compounds that could provide the basis of new drugs

The credit crunch is strangling biotech. And with no access to capital, the only way out is to sell to big pharma.

Pharmaceutical companies need to replenish their portfolios. But are biologics the way to go? Part 2 of Nuala Moran's report from Düsseldorf.